1. Home
  2. CBNK vs OCGN Comparison

CBNK vs OCGN Comparison

Compare CBNK & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBNK

Capital Bancorp Inc.

HOLD

Current Price

$31.50

Market Cap

440.4M

Sector

Finance

ML Signal

HOLD

Logo Ocugen Inc.

OCGN

Ocugen Inc.

HOLD

Current Price

$1.34

Market Cap

387.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBNK
OCGN
Founded
1974
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
440.4M
387.3M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
CBNK
OCGN
Price
$31.50
$1.34
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$34.50
$7.00
AVG Volume (30 Days)
40.2K
6.2M
Earning Date
01-26-2026
03-04-2026
Dividend Yield
1.49%
N/A
EPS Growth
60.85
N/A
EPS
3.41
N/A
Revenue
$230,026,000.00
$5,370,000.00
Revenue This Year
$14.13
$35.88
Revenue Next Year
$8.57
N/A
P/E Ratio
$9.45
N/A
Revenue Growth
34.78
14.26
52 Week Low
$24.69
$0.52
52 Week High
$36.40
$1.96

Technical Indicators

Market Signals
Indicator
CBNK
OCGN
Relative Strength Index (RSI) 68.23 40.65
Support Level $29.05 $1.41
Resistance Level $32.94 $1.70
Average True Range (ATR) 0.98 0.10
MACD 0.24 -0.04
Stochastic Oscillator 73.89 1.96

Price Performance

Historical Comparison
CBNK
OCGN

About CBNK Capital Bancorp Inc.

Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage, and also operates in five business segments: commercial banking; mortgage banking; credit cards; government loan servicing; and corporate activities.

About OCGN Ocugen Inc.

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Share on Social Networks: